BACKGROUND: Randomised trials show that male circumcision reduces the prevalence and incidence of high-risk human papillomavirus (HPV) infection in men. We assessed the efficacy of male circumcision to reduce prevalence and incidence of high-risk HPV in female partners of circumcised men. METHODS: In two parallel but independent randomised controlled trials of male circumcision, we enrolled HIV-negative men and their female partners between 2003 and 2006, in Rakai, Uganda. With a computer-generated random number sequence in blocks of 20, men were assigned to undergo circumcision immediately (intervention) or after 24 months (control). HIV-uninfected female partners (648 of men from the intervention group, and 597 of men in the control group) were simultaneously enrolled and provided interview information and self-collected vaginal swabs at baseline, 12 months, and 24 months. Vaginal swabs were tested for high-risk HPV by Roche HPV Linear Array. Female HPV infection was a secondary endpoint of the trials, assessed as the prevalence of high-risk HPV infection 24 months after intervention and the incidence of new infections during the trial. Analysis was by intention-to-treat. An as-treated analysis was also done to account for study-group crossovers. The trials were registered, numbers NCT00425984 and NCT00124878. FINDINGS: During the trial, 18 men in the control group underwent circumcision elsewhere, and 31 in theintervention group did not undergo circumcision. At 24-month follow-up, data were available for 544 women in the intervention group and 488 in the control group; 151 (27·8%) women in the intervention group and 189 (38·7%) in the control group had high-risk HPV infection (prevalence risk ratio=0·72, 95% CI 0·60-0·85, p=0·001). During the trial, incidence of high-risk HPV infection in women was lower in the intervention group than in the control group (20·7 infections vs 26·9 infections per 100 person-years; incidence rate ratio=0·77, 0·63-0·93, p=0·008). INTERPRETATION: Our findings indicate that male circumcision should now be accepted as an efficacious intervention for reducing the prevalence and incidence of HPV infections in female partners. However, protection is only partial; the promotion of safe sex practices is also important. FUNDING: The Bill & Melinda Gates Foundation, National Institutes of Health, and Fogarty International Center. Copyright Â
RCT Entities:
BACKGROUND: Randomised trials show that male circumcision reduces the prevalence and incidence of high-risk humanpapillomavirus (HPV) infection in men. We assessed the efficacy of male circumcision to reduce prevalence and incidence of high-risk HPV in female partners of circumcised men. METHODS: In two parallel but independent randomised controlled trials of male circumcision, we enrolled HIV-negative men and their female partners between 2003 and 2006, in Rakai, Uganda. With a computer-generated random number sequence in blocks of 20, men were assigned to undergo circumcision immediately (intervention) or after 24 months (control). HIV-uninfected female partners (648 of men from the intervention group, and 597 of men in the control group) were simultaneously enrolled and provided interview information and self-collected vaginal swabs at baseline, 12 months, and 24 months. Vaginal swabs were tested for high-risk HPV by Roche HPV Linear Array. Female HPV infection was a secondary endpoint of the trials, assessed as the prevalence of high-risk HPV infection 24 months after intervention and the incidence of new infections during the trial. Analysis was by intention-to-treat. An as-treated analysis was also done to account for study-group crossovers. The trials were registered, numbers NCT00425984 and NCT00124878. FINDINGS: During the trial, 18 men in the control group underwent circumcision elsewhere, and 31 in the intervention group did not undergo circumcision. At 24-month follow-up, data were available for 544 women in the intervention group and 488 in the control group; 151 (27·8%) women in the intervention group and 189 (38·7%) in the control group had high-risk HPV infection (prevalence risk ratio=0·72, 95% CI 0·60-0·85, p=0·001). During the trial, incidence of high-risk HPV infection in women was lower in the intervention group than in the control group (20·7 infections vs 26·9 infections per 100 person-years; incidence rate ratio=0·77, 0·63-0·93, p=0·008). INTERPRETATION: Our findings indicate that male circumcision should now be accepted as an efficacious intervention for reducing the prevalence and incidence of HPV infections in female partners. However, protection is only partial; the promotion of safe sex practices is also important. FUNDING: The Bill & Melinda Gates Foundation, National Institutes of Health, and Fogarty International Center. Copyright Â
Authors: Ronald H Gray; David Serwadda; Xiangrong Kong; Frederick Makumbi; Godfrey Kigozi; Patti E Gravitt; Stephen Watya; Fred Nalugoda; Victor Ssempijja; Aaron A R Tobian; Noah Kiwanuka; Lawrence H Moulton; Nelson K Sewankambo; Steven J Reynolds; Thomas C Quinn; Boaz Iga; Oliver Laeyendecker; Amy E Oliver; Maria J Wawer Journal: J Infect Dis Date: 2010-05-15 Impact factor: 5.226
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: S K Kjaer; E M de Villiers; C Dahl; G Engholm; J E Bock; B F Vestergaard; E Lynge; O M Jensen Journal: Int J Cancer Date: 1991-04-22 Impact factor: 7.396
Authors: Xavier Castellsagué; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Silvia de Sanjose; José Eluf-Neto; Corazon A Ngelangel; Saibua Chichareon; Jennifer S Smith; Rolando Herrero; Victor Moreno; Silvia Franceschi Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: L A Brinton; W C Reeves; M M Brenes; R Herrero; E Gaitan; F Tenorio; R C de Britton; M Garcia; W E Rawls Journal: Int J Cancer Date: 1989-08-15 Impact factor: 7.396
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Maria J Wawer; Frederick Makumbi; Godfrey Kigozi; David Serwadda; Stephen Watya; Fred Nalugoda; Dennis Buwembo; Victor Ssempijja; Noah Kiwanuka; Lawrence H Moulton; Nelson K Sewankambo; Steven J Reynolds; Thomas C Quinn; Pius Opendi; Boaz Iga; Renee Ridzon; Oliver Laeyendecker; Ronald H Gray Journal: Lancet Date: 2009-07-18 Impact factor: 79.321
Authors: Bethany A Weaver; Qinghua Feng; King K Holmes; Nancy Kiviat; Shu-Kuang Lee; Christine Meyer; Mike Stern; Laura A Koutsky Journal: J Infect Dis Date: 2004-01-29 Impact factor: 5.226
Authors: Aaron A R Tobian; Victor Ssempijja; Godfrey Kigozi; Amy E Oliver; David Serwadda; Frederick Makumbi; Frederick K Nalugoda; Boaz Iga; Steven J Reynolds; Maria J Wawer; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2009-07-31 Impact factor: 4.177
Authors: Aaron A R Tobian; Godfrey Kigozi; Andrew D Redd; David Serwadda; Xiangrong Kong; Amy Oliver; Fred Nalugoda; Thomas C Quinn; Ronald H Gray; Maria J Wawer Journal: J Infect Dis Date: 2011-12-05 Impact factor: 5.226
Authors: Supriya D Mehta; Charlotte Gaydos; Ian Maclean; Elijah Odoyo-June; Stephen Moses; Lawrence Agunda; Nicole Quinn; Robert C Bailey Journal: Sex Transm Dis Date: 2012-04 Impact factor: 2.830
Authors: Aaron A R Tobian; Godfrey Kigozi; Patti E Gravitt; Changchang Xiao; David Serwadda; Kevin P Eaton; Xiangrong Kong; Maria J Wawer; Fred Nalugoda; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2012-07-31 Impact factor: 4.177
Authors: Jason Bailey Reed; Emmanuel Njeuhmeli; Anne Goldzier Thomas; Melanie C Bacon; Robert Bailey; Peter Cherutich; Kelly Curran; Kim Dickson; Tim Farley; Catherine Hankins; Karin Hatzold; Jessica Justman; Zebedee Mwandi; Luke Nkinsi; Renee Ridzon; Caroline Ryan; Naomi Bock Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: Rachel T Esra; Abraham J Olivier; Jo-Ann S Passmore; Heather B Jaspan; Rushil Harryparsad; Clive M Gray Journal: Front Immunol Date: 2016-06-24 Impact factor: 7.561